Provided by Tiger Trade Technology Pte. Ltd.

BrainStorm Cell Therapeutics Inc.

0.5775
-0.0060-1.03%
Volume:5.95K
Turnover:3.38K
Market Cap:6.37M
PE:-0.41
High:0.6200
Open:0.5553
Low:0.5551
Close:0.5835
52wk High:1.93
52wk Low:0.5400
Shares:11.03M
Float Shares:10.28M
Volume Ratio:0.46
T/O Rate:0.06%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4200
EPS(LYR):-2.3145
ROE:-1121.89%
ROA:-400.07%
PB:-0.83
PE(LYR):-0.25

Loading ...

Company Profile

Company Name:
BrainStorm Cell Therapeutics Inc.
Exchange:
OTCQB
Establishment Date:
2000
Employees:
23
Office Location:
1325 Avenue of Americas,28th Floor,New York,New York,United States
Zip Code:
10019
Fax:
- -
Introduction:
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.